

Procedure file

| Basic information | | |
|---|--------------------------------|-------------------------------|
| CNS - Consultation procedure Regulation | 1997/0255(CNS) | Procedure lapsed or withdrawn |
| Decentralized Community agencies: Agency for the evaluation of medicinal products | | |
| Subject 8.40.08 Agencies and bodies of the EU | | |

| Key players | | | |
|-------------------------------|-------------------------------|--|------------|
| European Parliament | Committee responsible | Rapporteur | Appointed |
| | CONT Budgetary Control | | 25/11/1997 |
| | | PPE KELLETT-BOWMAN Edward T. | |
| | Committee for opinion | Rapporteur for opinion | Appointed |
| | BUDG Budgets | | 27/10/1997 |
| | | PSE TAPPIN Michael | |
| Council of the European Union | | | |

| Key events | | | |
|------------|---|---|---------|
| 06/10/1997 | Legislative proposal published | COM(1997)0489 | Summary |
| 21/11/1997 | Committee referral announced in Parliament | | |
| 21/01/1998 | Vote in committee | | Summary |
| 21/01/1998 | Committee report tabled for plenary, 1st reading/single reading | A4-0035/1998 | |
| 09/03/1998 | Debate in Parliament |  | |
| 10/03/1998 | Decision by Parliament | T4-0120/1998 | Summary |
| 30/04/1998 | Modified legislative proposal published | COM(1998)0289 | Summary |
| 17/07/2002 | End of procedure in Parliament | | |

| Technical information | |
|-----------------------|------------------------------|
| Procedure reference | 1997/0255(CNS) |
| Procedure type | CNS - Consultation procedure |

| | |
|----------------------------|------------------------------------|
| Procedure subtype | Legislation |
| Legislative instrument | Regulation |
| Legal basis | EC Treaty (after Amsterdam) EC 308 |
| Stage reached in procedure | Procedure lapsed or withdrawn |

Documentation gateway

| | | | | |
|---|--|------------|----|---------|
| Legislative proposal | COM(1997)0489 | 06/10/1997 | EC | Summary |
| Committee report tabled for plenary, 1st reading/single reading | A4-0035/1998 OJ C 080 16.03.1998, p. 0003 | 21/01/1998 | EP | |
| Text adopted by Parliament, 1st reading/single reading | T4-0120/1998 OJ C 104 06.04.1998, p. 0021-0047 | 10/03/1998 | EP | Summary |
| Modified legislative proposal | COM(1998)0289 | 30/04/1998 | EC | Summary |

Additional information

| | |
|---------------------|-------------------------|
| European Commission | EUR-Lex |
|---------------------|-------------------------|

Decentralized Community agencies: Agency for the evaluation of medicinal products

OBJECTIVE: to amend Regulation (EEC) No 2309/93 establishing the Agency for the Evaluation of Medicinal Products in order to modify the regulatory framework governing the management of the Agency's budget. CONTENT: the proposed changes relate to: - power of discharge: as this body is partly self-sufficient as far as its resources are concerned, a joint power of discharge is proposed. Discharge will be given by the board of directors to the director of the Agency, at the recommendation of the European Parliament; - own resources: as the Agency has resources other than those from its annual budgetary allocation, it is proposed that surplus revenue be paid back into the general budget of the European Union once a reserve has been set up to meet any future expenditure. The sums allocated to this reserve must be agreed by the Commission, after consulting the European Parliament; - financial control: financial control of the Agency will be carried out by the Commission's Financial Controller.?

Decentralized Community agencies: Agency for the evaluation of medicinal products

In adopting the report by Mr Edward T. KELLETT-BOWMAN (PPE, UK) on the amendments to the basic regulation on the Agency for the Evaluation of Medicinal Products, Parliament welcomed the Commission proposal, which addressed issues of long-standing concern to Parliament with regard to the discharge and financial control of the decentralized bodies. However, Parliament called for: -all of the Agency's revenue to be budgetized and regarded as preallocated resources of the European Union, -all surplus revenue to be paid back into the general budget of the Union, -no amounts to be taken out of the reserve in the Agency's budget without the agreement of Parliament, -the Financial Controller to ensure that the necessary practical arrangements are in place to allow swift and effective processing of the Agency's financial transactions and to prevent excessive recourse to the use of imprest accounts, -the Commission to evaluate the level of the fees received by the Agency after three years. It also recalled that it was a prerequisite to involve Parliament in the discharge procedure.?

Decentralized Community agencies: Agency for the evaluation of medicinal products

In its amended proposal the Commission supported Parliament's amendments concerning the involvement of Parliament in the discharge procedure. However, the Commission did not take over the amendments on the own resources of this agency or those on any surplus revenue reverting to the Community budget. ?